Abstract
We have partially purified an archaebacterial protein of 84 kD which shares common epitopes with the human c-myc protein as shown by its cross-reactivity with a commercialized anti-human c-myc antiserum. An antiserum raised against the 84 kD protein recognizes a 60 kD protein from HL-60 nuclei. This protein is also recognized by the anti-human c-myc antiserum. Using this archaebacterial protein as antigen for Western blot analysis, we found that the human c-myc oncogene product could be immunogenic and that it is possible, in some spontaneously occurring human tumours, to detect antibodies against the c-myc gene product in the serum of cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ben-Mahrez, K., Thierry, D., Sorokine, I. et al. Detection of circulating antibodies against c-myc protein in cancer patient sera. Br J Cancer 57, 529–534 (1988). https://doi.org/10.1038/bjc.1988.123
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.123
This article is cited by
-
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices
Nature Biotechnology (1999)
-
Biotechnological applications and potentialities of halophilic microorganisms
World Journal of Microbiology & Biotechnology (1995)
